Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 2, 2002, Pages 112-122

  Tennezé, Laurent ^a,b   Tarral, Eliane ^a,b   Ducloux, Nicole ^a,b   Funck Brentano, Christian ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; FLECAINIDE ACETATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; HUMAN; IMMEDIATE RELEASE FORMULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; HEART CONDUCTION SYSTEM; HUMANS; MALE; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0036694258     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.125946     Document Type: Article

References (40)

1. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
2. Effects of class I drugs on atrial fibrillation
3. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias
4. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias
5. Flecainide
6. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation
7. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia
8. Flecainide acetate for treatment of tachyarrhythmias in children: Review of world literature on efficacy, safety, and dosing
9. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias
10. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs
11. Flecainide acetate in atrial flutter and fibrillation: The arrhythmogenic effects
12. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation
13. Events in the cardiac arrhythmia suppression trial: Baseline predictors of mortality in placebo-treated patients
14. Amplification of flecainide-induced ventricular conduction slowing by exercise: A potentially significant clinical consequence of use-dependent sodium channel blockade
15. Life-threatening flecainide toxicity: A pharmacodynamic approach
16. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone
17. Flecainide acetate: Concentration-response relationships for antiarrhythmic and electrocardiographic effects
18. Pharmacodynamic variability of flecainide assessed by QRS changes
19. Pharmacodynamics and side effects of flecainide acetate
20. Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients
21. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies
22. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide
23. Flecainide: Evidence of non-linear kinetics
24. The relationship between paroxetine and the sparteine oxidation polymorphism
25. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
26. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination
27. Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for high-performance liquid chromatographic analysis - Fluorescence or ultraviolet detection
28. High-performance liquid chromatographic method for the quantitation of flecainide, a new antiarrhythmic, in human plasma and urine
29. Bioavailability and bioequivalence of pharmaceutical formulations
30. Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I
31. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs
32. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)
33. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
34. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial
35. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect
36. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST)
37. Malignant arrhythmias and acute myocardial ischemia: Interaction between flecainide and the autonomic nervous system
38. Drug therapy: Flecainide
39. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans
40. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo